Menu

Pharma News

Generics Blue Cap V13C15

UCB sells generics unit to Lannett

Home/Pharma News | Posted 11/09/2015

Belgium-based biopharmaceutical company UCB announced on 2 September 2015 that it would sell its US specialty generics business, Kremers Urban, to US generics company Lannett for US$1.23 billion in cash plus contingent payments.

Shaking hands V13D29

US FTC clears Pfizer’s purchase of Hospira

Home/Pharma News | Posted 04/09/2015

Pharma giant Pfizer announced on 24 August 2015 that the US Federal Trade Commission (FTC) terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Pfizer’s pending acquisition of US-based injectable generics specialist and biosimilars maker Hospira.

Australia flag V13C29

ANI Pharma and IDT Australia collaborate on US generics

Home/Pharma News | Posted 28/08/2015

US-based brand-name and generic drugmaker ANI Pharmaceuticals (ANI) announced on 12 August 2015 that it had entered into a collaboration with generics company IDT Australia (IDT) to commercialize up to 18 previously marketed US generics.

picture 66

Mergers between Watson/Actavis and ANI Pharma/BioSante

Home/Pharma News | Posted 19/10/2012

Mergers are once again on the agenda as companies strive to meet the constant demands of governments to cut costs and yet still make a profit.

Shaking hands V13D29

AstraZeneca and Fujifilm Kyowa Kirin Biologics to collaborate on bevacizumab biosimilar

Home/Pharma News | Posted 21/08/2015

Japanese biosimilars maker Fujifilm Kyowa Kirin Biologics announced on 24 July 2015 that it had entered into an agreement with pharma giant AstraZeneca to establish a joint venture for the development and commercialization of its candidate biosimilar, FKB238.

picture 84

Hikma to acquire Boehringer Ingelheim’s US generics business

Home/Pharma News | Posted 21/08/2015

Jordan-based drugmaker Hikma Pharmaceuticals (Hikma) announced on 28 July 2015 that it had made a deal with Germany’s Boehringer Ingelheim to acquire the latter’s US generics business: Roxane Laboratories and Boehringer Ingelheim Roxane (Roxane).

Shaking hands V13D29

Lupin to expand US generics business with Gavis acquisition

Home/Pharma News | Posted 07/08/2015

Indian generics manufacturer Lupin Pharmaceuticals (Lupin) announced on 23 July 2015 that it had entered into a definitive agreement to acquire US generics makers Gavis Pharmaceuticals and Novel Laboratories (Gavis).

Shaking hands V13D29

Acquisitions for Endo and Strides

Home/Pharma News | Posted 26/06/2015

Endo Pharmaceuticals (Endo) and Strides Arcolab (Strides) are both looking at acquisitions as a way to expand their generics businesses.

Shaking hands V13D29

Amneal to acquire Australian generics business from Actavis

Home/Pharma News | Posted 15/05/2015

Privately held US generics maker Amneal Pharmaceuticals (Amneal) announced on 31 March 2015 that it had made a deal with the Australian subsidiary of Actavis to acquire the Australian generics business of Actavis for an undisclosed amount.

88 MD002468

Anticompetitive acquisition forces generics sale

Home/Pharma News | Posted 08/05/2015

US generics maker CorePharma has had to sell its rights of two generics in order to merge with fellow US drug company Impax Laboratories (Impax). The US Federal Trade Commission (FTC) ruled that Impax’s acquisition of CorePharma would have been anticompetitive unless CorePharma sold its rights and assets for pilocarpine, a drug used to treat dry mouth and glaucoma, and ursodiol, a treatment for liver and gall bladder diseases.